FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Expires: December 31, 2014 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person * MANWANI HARISH (Last) (First) (Middle) 333 LAKESIDE DRIVE (Street) FOSTER CITY CA 94404 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol GILEAD SCIENCES INC [ GILD ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 05/05/2020
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/05/2020		M		2,270	A	(1)	4,137	D
Common Stock	05/05/2020		F		419	D	$ 79.14	3,718	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	05/05/2020		M			2,270	(2)	(2)	Common Stock	2,270	(1)	0	D
Restricted Stock Unit	(1)	05/06/2020		A		1,936		(3)	(3)	Common Stock	1,936	(1)	1,936	D
Non-qualified Stock Option (Right to Buy)	$ 77.47	05/06/2020		A		7,886		(4)	05/06/2030	Common Stock	7,886	$ 0	7,886	D

Explanation of Responses:

1. Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

2. 100% of the restricted stock units will vested on May 5, 2020.

3. 100% of the restricted stock units will vest upon the earlier of May 6, 2021 or the day immediately preceding the next regular annual stockholders meeting.

4. 25% of the shares subject to the option vest on each three-month anniversary from May 6, 2020 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 6, 2021 or the day immediately preceding the next regular annual stockholders meeting.

	/s/ Amy Kim by Power of Attorney for Harish Manwani	05/07/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Power of Attorney

	Know all by these presents, that the undersigned hereby 
constitutes and appoints each of Amy Kim, Jason Okazaki and Diane Wilfong, 
signing individually, the undersigned?s true and lawful 
attorneys-in-fact and agents to:

(1) execute for and on behalf of the undersigned, an officer or 
director of Gilead Sciences, Inc. (the ?Company?), Forms 3, 4 and 
5 in accordance with Section 16(a) of the Securities Exchange Act of 
1934, as amended (the ?Exchange Act?) and the rules there under;

(2) do and perform any and all acts for and on behalf of the undersigned
that may be necessary or desirable to complete and execute such Form 3, 4 
or 5, complete and execute and amendment or amendments thereto, and timely 
file such forms or amendments with United States Securities and Exchange 
Commission and any stock exchange or similar authority; and

(3) take any other action of any nature whatsoever in connection with the   
foregoing which, in the opinion of such attorney-in-fact, may be of 
benefit, in the best interest of, or legally required by, the 
undersigned, it being understood that the documents executed by such 
attorney-in-fact on behalf of the undersigned pursuant to this 
Power of Attorney shall be in such form and shall contain such terms 
and conditions as such attorney-in-fact may approve in such 
attorney-in-fact?s discretion.

	The undersigned hereby grants to each such attorney-in-fact full 
power and authority to do and perform any and every act and thing 
whatsoever requisite, necessary, or proper to be done in the exercise of 
any of the rights and powers herein granted, fully to all intents and 
purpose as the undersigned might or could do if personally present, with 
full power of substitution or revocation, hereby ratifying and confirming 
all that such attorney-in-fact, or such attorney-in-fact?s substitute or 
substitutes, shall lawfully do or cause to be done by virtue of this power 
of attorney and the rights and powers herein granted. The undersigned 
acknowledges that the foregoing attorneys-in-fact, in serving in such 
capacity at the request of the undersigned, are not assuming, nor is the 
Company assuming, any of the undersigned?s responsibilities to comply 
with Section 16 of the Exchange Act.

	This Power of Attorney shall remain in full force and effect 
until the earliest to occur of (a) the undersigned is no longer required
to file Forms 3, 4 and 5 with respect to the undersigned?s holdings of 
and transactions in securities issued by the Company, (b) revocation by 
the undersigned in a signed writing delivered to the foregoing 
attorney?s-in-fact or (c) as to any attorney-in-fact individually, until
such attorney-in-fact shall no longer be employed by the Company.

 	IN WITNESS WHEREOF, the undersigned has caused this Power of 
Attorney to be executed as of this 20th day of November, 2019.


/s/Harish Manwani








	

SEC Filings